Resumen de New Drug for Late-Stage Breast Cancer

Diane S. Aschenbrenner

• * Ado-trastuzumab emtansine (Kadcyla) is a new drug labeled for the treatment of metastatic HER2-positive breast cancer after other therapy has been unsuccessful.

  * The drug can cause hepatotoxicity, cardiac toxicity (including fatal), death of an embryo or fetus, and birth defects.